Expertise in
3
conditions

Colin R. Lindsay

Manchester, ENG, GB 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
3
conditions
Manchester, ENG, GB 

Overview

Colin Lindsay practices in Manchester, United Kingdom. Mr. Lindsay is highly rated in 3 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Melanoma, and Thymic Epithelial Tumor.

His clinical research consists of co-authoring 62 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Manchester, ENG, United Kingdom
Other Locations
199 Cathedral Street, Glasgow, SCT G40QU, United Kingdom
Angel Building 407 St John Street, London, ENG EC1V4AD, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic

62 Total Publications

Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule Inhibitor.
Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule Inhibitor.
Journal: JCO precision oncology
Published: November 14, 2025

Frequently Asked Questions about Colin R. Lindsay

Is Colin R. Lindsay a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Colin R. Lindsay is classified as an Distinguished expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Colin R. Lindsay participate in research or clinical trials?

Yes. Colin R. Lindsay has published 62 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Colin R. Lindsay's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lindsay's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile